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Abstract To examine the cellular basis for secretion defect-type 
antithrombin deficiency, we expressed two mutants, P->stop 
(Pro429 to stop codon) and AGlu (deletion of Glu313). Pulse-chase 
experiments using stably transfected BHK cells showed that little 
( < 5%) of P —> stop mutant as well as AGlu mutant was secreted 
and the total amount of radioactivity was significantly reduced, 
suggesting an intracellular degradation. The degradation was not 
inhibited by brefeldin A, indicating it occurring in a preGolgi 
apparatus. However, the degradation was strongly inhibited by 
proteasomal inhibitors, such as carbobenzoxy-L-leucyl-L-leucyl-
L-leucinal (LLL), carbobenzoxy-L-leucyl-L-leucyl-L-norvalinal 
(LLnV) and lactacystin. By endoglycosidase H digestion and 
immunofluorescence staining, these mutants were shown to 
localize in the endoplasmic reticulum (ER). These results suggest 
that the secretion defect-type mutants of antithrombin are 
degraded by proteasome through the ER-associated quality 
control mechanism in the cells. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Antithrombin, one of the major serine proteinase inhibitors 
in mammalian plasma, inhibits most of the coagulation pro-
teases. The inhibition of each protease by antithrombin is 
concomitant with the formation of a stable 1:1 molar complex 
and is enhanced as much as 1000-fold in the presence of 
heparin, a sulfated polysaccharide [1,2]. Human antithrombin 
is a 58 kDa glycoprotein consisting of 432 amino acid residues 
and three disulfide bridges [3]. Most of the circulating anti-
thrombin is post-translationally modified resulting in four 
Asn-linked oligosaccharides at positions 96, 135, 155, and 
192. Antithrombin has two functional domains; one is the 
NH2-terminal heparin-binding region and the other is the re-
active-site region of Arg393-Ser394 located in the COOH-ter-
minal region [1-3]. 
Inherited antithrombin deficiency is associated with a pre-
disposition to familial venous thromboembolic disease [4]. 
The deficiency has been classified into two types [5]: type I 
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Abbreviations: endo H, endoglycosidase H; ER, endoplasmic reticu-
lum; F1TC, fluorescein isothiocyanate; LLnL, JVa-acetyl-L-leucyl-L-
leucyl-L-norleucinal; LLL, carbobenzoxy-L-leucyl-L-leucyl-L-leucinal; 
LLnV, carbobenzoxy-L-leucyl-L-leucyl-L-norvalinal; PDI, protein di-
sulfide isomerase; Wt, wild-type 
('classical') deficiency is characterized by a reduced level of 
both the circulating antigen and its activity, and type II defi-
ciency is by production of variant protein, in which the anti-
gen is approximately normal but functional levels are reduced 
to 50% of that of normal. At present, a total of 128 distinct 
mutations have been compiled in the antithrombin deficiency 
database, 93 cases (73%) of which belong to type I deficiency 
[6]. However, cellular mechanism for the type I antithrombin 
deficiency has not been understood well. 
To examine the secretion defect resulting in antithrombin 
deficiency, we expressed two mutants of type I deficiency, 
AGlu (deletion of Glu313) and P->stop (Pro429 ->stop codon). 
The proband of AGlu mutant showed 47% for antigen and 
57% for functional activity of antithrombin [7]. P->stop mu-
tant was studied from the result of the study on cci -proteinase 
inhibitor that COOH-terminal truncation to Pro391 (Pro429 in 
antithrombin) of oci -proteinase inhibitor led to a secretion 
defect [8]. In this communication, we show that the type I 
deficiency (secretion defect) of antithrombin is caused by an 
intracellular degradation of mutant proteins by proteasome 
through the quality control mechanism in the cells. 
2. Materials and methods 
2.1. Materials 
Full-length human antithrombin cDNA was prepared from a hu-
man liver cDNA library (Clonetech) and its nucleotide sequence [3] 
confirmed. Rabbit anti-human antithrombin antiserum was prepared 
as described previously [9], and rabbit anti-bovine PDI antiserum was 
kindly provided by Prof. Masakazu Kikuchi (Ritsumeikan University, 
Kyoto). FITC-labeled sheep anti-rabbit IgG (H+L) and FITC-labeled 
wheat germ lectin were obtained from The Binding Site (Birmingham, 
UK) and Sigma Chemicals (St. Louis, MO), respectively. Brefeldin A 
and LLnL were purchased from Sigma Chemicals. LLL and LLnV 
were obtained from Peptide Institute Inc. (Osaka). Lactacystin was 
prepared from Streptomyces sp. OM-6519 as described [10]. 
2.2. Construction of the expression vector and transfection to cells 
Site-directed mutagenesis of antithrombin mutants was performed 
with the Sculptor in vitro mutagenesis system (Amersham) and 17-mer 
mutagenic primers. Primers used were as follows: AGlu, 5'-GCAT-
CATCTCCAATTCATCCAG-3' (complementary sequence of Nos. 
1019-1042 of antithrombin [3] with deletion of codon (GGA) for 
Glu313) and P^stop, 5'-TTACTTAACACACATTAGTTGGC-
TACTCT-3' (complementary sequence of Nos. 1369-1395, mutagenic 
TTA is underlined). Mutations were verified by sequence analyses. 
The cDNAs for wild-type (Wt) and mutant antithrombin were ligated 
into the EcoKl site of pcD2-SRa expression vector [11], and these 
expression vectors were purified by CsCl gradient ultracentrifugation. 
Seven milligram of expression vector were transfected into 2X10" 
BHK cells by the calcium phosphate coprecipitation method [11]. 
To obtain stable transfectants, cells were selected by the addition of 
400 mg/ml G418 (Wako Pure Chemicals, Osaka). 
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2.3. Puke-chase, immunoprecipitation, and gel electrophoresis 
To examine the secretion rate and intracellular localization of re-
combinant antithrombin mutants, pulse-chase analysis and endo H 
digestion were performed as described previously [12,13]. 
2.4. Immunofluorescence 
To examine the subcellular localization of recombinant antithrom-
bin in transfected cells, immunofluorescence analysis was performed 
as described previously [12,13]. The rabbit anti-human antithrombin 
antibody was stained with FITC-labeled sheep anti-rabbit antibody. 
For organelle markers of the ER and Golgi apparatus, rabbit anti-
bovine PDI antiserum and FITC-labeled wheat germ lectin, respec-
tively, were employed. 
3. Results 
3.1. Identification of intracellular degradation of antithrombin 
mutants 
To examine the secretion efficiency of antithrombin mu-
tants, pulse-chase experiments were performed first. Fig. 1 
shows the SDS-PAGE of Wt antithrombin, P->stop and 
AGlu mutants. In Wt-expressing cells, the majority of the 
pulse-labeled radioactivity was recovered from the medium 
after a 2 h chase, and the total amount of radioactivity was 
maintained during the chase period (Fig. 1A). In contrast, 
little ( < 5%) of P -> stop mutant was secreted into the medium 
during the chase period and a significant reduction in the total 
amount of radioactivity was observed (Fig. IB). Pulse-chase 
analysis of AGlu mutant-expressing cells showed a similar but 
slightly better secretion pattern when compared with that of 
P->stop mutant cells (Fig. 1C). The time for 50% disappear-
ance of the total amount of radioactivity in P->stop and 
AGlu mutants cells were estimated to be 5.7 and 3.3 h, respec-
tively. These results suggest that P -> stop and AGlu mutants 
of antithrombin are degraded intracellularly. 
To further examine the intracellular degradation of these 
antithrombin mutants, we performed pulse-chase experiments 
in the presence of a transport inhibitor, brefeldin A, and pro-
tease inhibitors (Fig. 2). In these experiments, antithrombin in 
cell extracts and in the conditioned medium was immunopre-
cipitated, followed by SDS-PAGE analysis and detected by 
autoradiography (Fig. 2A). By taking the amount of radio-
activity in cell extracts derived from 1 h pulse-labeled cells as 
100%, 71%o and 8% of the radioactivity were detected in the 
cell extracts and medium, respectively, of 8 h chased Wt cells. 
In contrast, in P->stop mutant cells, 21% and 2%, and in 
AGlu mutant cells, 6% and 9% of the radioactivity were de-
tected in the 8 h chased cell extracts and medium, respectively. 
Therefore, in P-»stop and AGlu mutants cells, there were 
77%o and 85%, respectively, disappearance of the pulse-labeled 
radioactivity during the 8 h chase period (Fig. 2B). In the 
presence of brefeldin A, almost all the pulse-labeled Wt was 
recovered from the cell extracts of 8 h chased cells. In con-
trast, in P -> stop and AGlu mutants cells, about 67% of the 
total amount of radioactivity disappeared during an 8 h chase 
period in the presence of 3 ug/ml brefeldin A. Brefeldin A is 
an inhibitor of intracellular transport by redistributing Golgi 
proteins into the ER and preventing further movement 
through the secretory pathway [14]. These results suggest 
that both P->stop and AGlu mutants were selectively de-
graded and brefeldin A had no apparent effects on the degra-
dation (Fig. 2B). 
To determine the specificity of the protease responsible for 
the intracellular degradation of P->stop mutant, various 
Fig. 1. Pulse-chase analysis of Wt antithrombin and P->stop and 
AGlu mutants in stably transfected BHK cells. A: Stable BHK cells 
were pulse-labeled for 1 h with 100 uCi/ml EXPRE35S35S (a mixture 
of [35S]Met and [35S]Cys, NEN) and chased for 0, 0.5, 1, 2, 4, and 
8 h. Labeled antithrombin from cell extracts and from the medium 
were immunoprecipitated and analyzed on 12.5% SDS-PAGE. B: In 
the kinetic analyses, the amount of radioactivity in the pulse-labeled 
cell extracts, quantitated by Bio-Imaging Analyzer (Fuji Film), is 
taken as 100%, and relative radioactivities of intracellular (•) and 
secreted fractions (o) are shown. Sum of the radioactivities of both 
fractions at each time is shown by open squares (□). 
types of membrane-permeable protease inhibitors were exam-
ined. LLL and LLnV known as potent synthetic proteasomal 
inhibitors [15], strongly inhibited the intracellular degradation 
of both P -> stop and AGlu mutants, and almost all the pulse-
labeled radioactivity was maintained intracellularly after the 
8 h chase (Fig. 2B). The order of the potency of inhibitors, 
LLnV-LLL > LLnL, agreed well with the inhibitor spectra 
for pro teasome [15]. Lactacystin, known as a specific inhibitor 
for proteasome through modifying the active threonine resi-
due of P-type proteasome subunits [16], also strongly inhibited 
the intracellular degradation of these mutants, suggesting pro-
teasome is responsible for the intracellular degradation of 
both P->stop and AGlu mutants. These results suggest that 
both mutants are degraded principally through the same cel-
lular mechanism. In Wt antithrombin-transfected cells, the 
total amount of radioactivity was unchanged during the chase 
period in the presence of these proteasomal inhibitors (Fig. 
2B), indicating these inhibitors had no inhibitory effect on the 
secretion of Wt antithrombin. Leupeptin and E64(d) known 
to inhibit the activities of ER proteases, ER60 and ER72, in 
vitro [17,18], had no effects on the secretion of Wt antithrom-
bin nor the degradation of two antithrombin mutants. Also 
other protease inhibitors against aminopeptidase (amastatin), 
cysteine proteases (antipain and E64), elastase (elastatinal) 
and metal proteases (phosphoramidon) showed no effect 
(data not shown). Furthermore, lysosomotropic agents, chlor-
oquine and NH4CI, which accumulate in lysosomes and ele-
vate the intravesicular pH by virtue of their weak basic prop-
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Fig. 2. Effects of brefeldin A and proteasomal inhibitors on the secretion and degradation of Wt antithrombin and P -»stop and AGlu mutants. 
A: Stably transfected BHK cells expressing Wt antithrombin, P->stop and AGlu mutants were pulse-labeled for 1 h with 50 itCi/ml of 
EXPRE35S35S and then chased for 8 h in the presence of various inhibitors. Antithrombin in the cell extracts and in the conditioned medium 
were immunoprecipitated, followed by SDS-PAGE analysis in the presence of 2-mercaptoethanol. Lane 1: Sample from 1 h pulse-labeled cells. 
Lane 2: Sample from 8 h chased cells without inhibitors. Lanes 3-7: Samples from 8 h chased cells in the presence of inhibitors: lane 3, 3 ug/ 
ml brefeldin A; lane 4, 50 |xM LLnL; lane 5, 50 uM LLL; lane 6, 50 uM LLnV; lane 7, 10 |xM lactacystin. B: Radioactivities of bands corre-
sponding to antithrombin in (A) were quantitated by Bio-Imaging Analyzer. Taking the radioactivity of pulse-labeled cell extracts as 100%, the 
relative radioactivities of antithrombin in cell extracts and medium are shown by closed and open bars, respectively. 
erties and then reduce the activities of lysosomal proteases 
[19], had no inhibitory effect on the degradation of antithrom-
bin mutants (data not shown). These results are inconsistent 
with a lysosomal or an autophagic degradation of the anti-
thrombin mutants. 
cence with that of AGlu mutant (data not shown). These 
results suggest that secretion defect mutants of antithrombin 
were predominantly localized in the ER. 
4. Discussion 
3.2. Intracellular localization of antithrombin mutants 
To examine the intracellular localization of the antithrom-
bin mutants, we used biochemical and morphological tech-
niques. First, 35S-labeled Wt antithrombin and P->stop and 
AGlu mutants were subjected to endo H digestion followed by 
SDS-PAGE analysis. About 10% of Wt antithrombin were 
endo H-resistant, while all the P -> stop and AGlu mutants 
were sensitive to endo H (data not shown), suggesting that 
the intracellular form of these mutants has carbohydrate 
chains of high mannose-type, localizing in the ER to the cis-
Golgi compartment. Secondly, we performed immunofluores-
cence staining of transiently AGlu mutant-transfected cells. 
The stained pattern of AGlu mutant (Fig. 3A) was identical 
with that of PDI, the ER-resident protein (Fig. 3B), but 
clearly distinct from that of wheat germ lectin, a Golgi marker 
that has a more localized, polar perinuclear stained pattern 
(Fig. 3C). P->stop mutant showed similar immunofluores-
Most of the type I antithrombin deficiencies are caused by a 
small insertion or deletion of bases in the gene, resulting in a 
frameshift mutation and usually a premature stop signal [6]. 
The AGlu mutant, however, is caused by an in-frame deletion 
of trinucleotides (GGA) at position 7644 to 7649 in the an-
tithrombin gene [7], suggesting that the deletion had no effect 
on the transcriptional or translational step. Since the proband 
of AGlu mutation showed a 50% antigen level compared to 
normal, the AGlu mutant of antithrombin was not thought to 
be secreted into the circulation. In this study, we observed 
that the AGlu mutant as well as the P -> stop mutant of an-
tithrombin showed an impaired secretion resulting in intra-
cellular degradation. This suggests that some type I deficien-
cies are caused by the intracellular degradation. Moreover, a 
conservative COOH-terminal Pro residue in serine proteinase 
inhibitors (serpins) was shown to be critical in the secretion of 
antithrombin (Fig. 1) as well as di-proteinase inhibitor [8], 
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Fig. 3. Immunofluorescence localization of the AGlu mutant. BHK 
cells that transiently expressed the AGlu mutant were stained with 
rabbit anti-human antithrombin IgG, followed by FITC-labeled 
sheep anti-rabbit IgG antibody (A). For organelle markers of the 
ER and the Golgi apparatus, PDI stained with rabbit anti-bovine 
PDI antiserum followed by FITC-labeled sheep anti-rabbit IgG anti-
body (B) and FITC-labeled wheat germ lectin (C), respectively, are 
shown. 
suggesting that full-length molecules are required for the se-
cretion of serpins and the disruption of a disumde bridge of 
antithrombin, Cys247-Cys430, caused the impaired secretion 
resulting in the intracellular degradation. This intracellular 
degradation was not inhibited by an ER-Golgi transport in-
hibitor (brefeldin A), indicating the degradation occurring in 
the preGolgi apparatus. The endo H digestion and immuno-
fluorescence analysis also suggest that the secretion defect 
mutants of antithrombin were predominantly localized in 
the ER (Fig. 3). Thus, the P-»stop and AGlu mutants were 
degraded through the quality control mechanism similar to 
cases of other proteins (see review [20,21]) and under-y-car-
boxylated protein C which we observed previously [12]. 
At present, a cysteine protease(s) inhibited by LLM and 
LLnL has been implicated in the degradation of HMG-CoA 
reductase [22], apolipoprotein B [23], and IgM [24], and a 
serine protease(s) inhibited by dichloroisocoumarin, tosyl-phe-
nylalanyl-chloromethyl ketone, and tosyl-lysyl-chloromethyl 
ketone is a candidate for IgM light chain breakdown [25]. 
Very recently, degradations of AF508 mutant of cystic fibro-
blast transmembrane conductance regulator (CFTR) [26,27], 
MHC class I heavy chain in cytomegarovirus-transfected cells 
[28] and glycosylphosphatidylinositol (GPI)-linked protein 
[29] were found to be inhibited by proteasomal inhibitors. 
In this study, we observed that inhibitors for proteasome, 
such as LLL, LLnV and lactacystin, showed potent inhibitory 
effects on the degradation of antithrombin mutants (Fig. 2). 
These inhibitor spectra strongly suggest that proteasome is 
responsible for the degradation of antithrombm mutants. 
We also observed that intracellular degradation of under-y-
carboxylated protein C is also inhibited by these proteasomal 
inhibitors (Tokunaga et al., submitted), suggesting not only 
ER-membrane anchoring proteins such as CFTR, MHC class 
I heavy chain and GPI-linked protein, but typical secretory 
proteins, such as antithrombin and protein C, are degraded by 
proteasome through the ER-associated quality control mech-
anism in the cells. 
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